Source BioScience Selects Indica Labs’ HALO AP® as the Digital Pathology Platform Powering the Future of NHS Outsourcing in the United Kingdom

Since deploying HALO AP® at its Nottingham headquarters, Source BioScience has processed 77,406 cases and 277,758 slides in under nine months with a national rollout now underway that will significantly expand digital pathology capacity across the UK’s outsourced histopathology market.

Albuquerque, NM, and Nottingham, September 8, 2026 – Indica Labs, the trusted global leader in AI-powered digital pathology and Source BioScience, the United Kingdom’s leading provider of histopathology services, today announced Source BioScience’s successful expansion of its digital pathology operation powered by HALO AP®. Since going live at Nottingham headquarters in October 2025, the organisation has demonstrated how an interoperable, scanner-agnostic enterprise platform can eliminate one of the greatest barriers to large-scale digital pathology outsourcing while enabling rapid laboratory growth.

For NHS trusts evaluating outsourcing partners, interoperability remains one of the greatest obstacles to digital pathology adoption. Differences in scanner hardware, laboratory information management systems (LIMS), and image formats often make it difficult to exchange digital slides and patient data efficiently across organisations. These technical barriers slow turnaround times, complicate workflows, and limit laboratories’ ability to scale digital pathology services.

HALO AP® addresses these challenges through a scanner-agnostic architecture that supports direct image transfer and automatic file format conversion, enabling referring sites to send digital slides to most scanner manufacturers. Direct LIMS-to-LIMS integration further streamlines the testing pathway by allowing orders, patient information, images, and reports to move seamlessly between organisations. The result is a fully digital workflow that shortens turnaround times by two to three days while improving traceability, compliance, and long-term image retention.

As a UKAS-accredited provider with laboratory locations in Nottingham, Chichester, and Cambridge, Source BioScience delivers comprehensive histopathology services across every subspecialty. The organisation supports more than 90 NHS trusts, works with over 280 consultant pathologists, reports more than 350,000 cases annually, and has scanned more than one million slides over the past year. Supported by dedicated couriers, laboratory integration, and technical services, Source BioScience consistently meets or exceeds NHS turnaround time requirements while helping healthcare providers address increasing diagnostic demand.

“We are proud to have selected HALO AP® as our digital pathology platform,” said Dr. Sindhu Menon, Deputy Medical Director for Source BioScience. “It’s robust, scalable, and intuitive environment has enabled us to efficiently manage high-volume workflows while streamlining case review, enhancing collaboration, and providing reliable access to digital pathology data. The exceptional training and ongoing support from the HALO AP® team were instrumental in ensuring smooth implementation and successful adoption across our organisation. HALO AP® plays an important role in our commitment to innovation and the continued advancement of digital pathology, and we value our partnership with Indica Labs as we continue to expand our digital capabilities.”

The last phase of Source BioScience’s digital transformation has involved getting HALO AP® implemented at its Chichester laboratory site. Both Nottingham and Chichester sites support private diagnostic services and NHS outsourcing, significantly expanding digital reporting capacity across the organisation. Additionally, Source BioScience plans to further expand its use of artificial intelligence within HALO AP®, beginning with AI-powered quality control and building toward future capabilities supporting clinical trials and AI-assisted pathology workflows.

“Large-scale digital pathology depends on interoperability,” said Steven Hashagen, CEO of Indica Labs. “Source BioScience has shown how an enterprise platform can remove integration barriers while supporting high-volume diagnostic workflows. We are excited to continue supporting their vision as they expand AI-enabled pathology services across the UK.”

With continued investment in digital pathology infrastructure, interoperability and scalable enterprise workflows, Source BioScience is positioning itself to become the United Kingdom’s premier outsourced digital histopathology partner for both NHS and private healthcare organisations.

Regulatory

HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP® is For Research Use Only in the USA and is not FDA cleared for clinical diagnostic use. In addition, HALO AP® provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.

About Indica Labs: Indica Labs, the global leader in AI-powered digital pathology, is redefining medicine with pathology platforms supporting life science discovery, translational research, clinical workflows, and companion diagnostic development. HALO platforms integrate image management and quantitative image analysis to deliver standardised, reproducible tissue-based analysis at every stage of the translational journey.

About Source BioScience: Source BioScience, comprised of Source LDPath and Source Genomics, provides industry-leading laboratory services in genomics, multiomics and healthcare diagnostics, partnering with biotechnology, pharmaceutical, healthcare and academia.

Source BioScience Media Contact:
Leisha Hankin
Leisha.Hankin@sourcebioscience.com

Indica Labs Media Contact:
Jenna Karpel
jkarpel@indicalab.com